ZIM Laboratories Limited ZIMLAB NSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India

https://www.zimlab.in

ZIM Laboratories Limited engages in the development, manufacture, and supply of generic pharmaceutical and nutraceutical products in India and internationally. It provides its products in pre- formulation intermediates and finished formulations in the oral solid dosage forms, such as pellets, taste-masked powders, granules, tablets, capsules, dry syrup, and oral thin films. The company offers therapeutics in the areas of urology, gastroenterology, antibiotics, anti-infectives, cardiovascular, central nervous system, NSAIDs/pain analgesics, and vitamins and supplements. The company was incorporated in 1984 and is based in Nagpur, India.

Market & Price

Market Cap

₹547.75 Cr

Current Price

₹102.29

High / Low (52W)

₹120.82 / ₹60.26

Beta

0.79

Valuation

Stock P/E

85.96

Industry PE

37.60

Forward P/E

PEG Ratio

Book Value

₹53.27

Price to Book

1.92

P/S

1.46

EV/EBITDA

13.22

Dividend Yield

Profitability & Returns

ROCE

6.14%

ROE

2.13%

ROA

1.24%

Profit Margin

1.56%

Op Margin

1.98%

EPS (Latest Qtr)

₹0.76

EPS (TTM)

₹1.19

Balance Sheet & Liquidity

Debt/Equity

0.43

Quick Ratio

0.80

Current Ratio

1.45

Debt

₹126.56 Cr

Total Assets

₹539.39 Cr

Current Assets

₹275.81 Cr

Working Capital

₹85.42 Cr

Ownership

Promoter Holding

71.35%

Chg in Prom Hold

FII / Inst Holding

0.00%

Chg in FII Hold

Financial Snapshot

Enterprise Value

₹396.71 Cr

Total Revenue (TTM)

₹374.40 Cr

EBITDA

₹30.01 Cr

Free Cash Flow

₹-13.06 Cr

Operating Cash Flow

₹49.53 Cr

Shares Outstanding

₹5.35 Cr

Gross Margin

55.83%

Payout Ratio

0.00%

Growth (CAGR)

Revenue 5Y

-1.24%

Profit 5Y

-37.95%

Revenue (YoY)

-3.30%

Earnings (YoY)

20.80%

PROS

In a confirmed uptrend (50-DMA above 200-DMA).

CONS

Trading at a high P/E of 86.0.
Revenue declined at -1.2% CAGR over 5 years.
Earnings shrank at -37.9% CAGR over 5 years.

* The pros and cons are auto-generated from financial metrics.

Price Chart

NSE TradingView Screener.in

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP ₹	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	ZIMLAB ZIM Laboratories Limited NSEPHARMA	102.29	85.96	₹547.75 Cr	-	6.14%	2.13%	-1.24%	-37.95%
2	SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA	1,799.20	37.59	₹4.32 L Cr	0.92%	17.94%	14.72%	10.39%	10.65%
3	DIVISLAB Divi's Laboratories Limited NSEPHARMA	6,667.00	68.97	₹1.77 L Cr	0.45%	18.96%	16.19%	11.27%	12.08%
4	TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA	4,410.80	68.96	₹1.49 L Cr	0.86%	9.06%	16.98%	13.27%	20.21%
5	CIPLA Cipla Limited NIFTY50NSEAIPHARMA	1,401.00	29.16	₹1.13 L Cr	0.93%	14.88%	11.74%	7.23%	11.45%
6	DRREDDY Dr. Reddy's Laboratories Limited NIFTY50NSEAIPHARMA	1,303.50	25.90	₹1.09 L Cr	0.61%	14.00%	11.83%	10.96%	-2.35%
7	ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA	1,077.70	21.51	₹1.08 L Cr	0.09%	19.24%	18.32%	16.55%	36.99%
8	LUPIN Lupin Limited NIFTY_MIDNSEPHARMA	2,267.70	19.49	₹1.04 L Cr	0.53%	28.42%	26.91%	19.10%	131.46%
9	MANKIND Mankind Pharma Limited NIFTY_MIDNSEPHARMA	2,375.60	51.29	₹98,090.71 Cr	0.08%	13.78%	12.45%	17.73%	14.28%

Quarterly Results

Figures in INR.

Metric	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	-	96.33 Cr	108.73 Cr	71.76 Cr	88.71 Cr	108.66 Cr	105.27 Cr
Cost of Revenue	-	41.25 Cr	48.26 Cr	30.01 Cr	39.64 Cr	48.60 Cr	47.12 Cr
Gross Profit	-	55.08 Cr	60.48 Cr	41.75 Cr	49.07 Cr	60.06 Cr	58.15 Cr
Operating Expenses	-	48.39 Cr	51.17 Cr	42.35 Cr	48.29 Cr	52.29 Cr	56.06 Cr
Operating Income	-	6.68 Cr	9.31 Cr	-60.48 L	77.26 L	7.77 Cr	2.09 Cr
EBITDA	-	13.32 Cr	16.31 Cr	5.74 Cr	7.80 Cr	14.51 Cr	13.35 Cr
Interest Expense	-	2.73 Cr	2.91 Cr	3.30 Cr	3.16 Cr	3.43 Cr	3.31 Cr
Pretax Income	-	5.70 Cr	8.11 Cr	-2.43 Cr	-34.38 L	6.05 Cr	4.94 Cr
Tax Provision	-	1.70 Cr	3.22 Cr	-55.71 L	8.08 L	1.65 Cr	1.20 Cr
Net Income	-	4.00 Cr	4.88 Cr	-1.87 Cr	-42.46 L	4.40 Cr	3.74 Cr
Diluted EPS	0.49	0.82	1.01	-0.38	-0.09	0.90	0.76

Profit & Loss (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Revenue	-	388.73 Cr	355.51 Cr	379.03 Cr	374.40 Cr
Cost of Revenue	-	199.94 Cr	172.37 Cr	167.85 Cr	165.37 Cr
Gross Profit	-	188.79 Cr	183.14 Cr	211.18 Cr	209.03 Cr
Operating Expenses	-	153.53 Cr	156.37 Cr	187.57 Cr	198.99 Cr
Operating Income	-	35.26 Cr	26.77 Cr	23.61 Cr	10.03 Cr
EBITDA	-	57.79 Cr	45.48 Cr	49.51 Cr	41.39 Cr
Interest Expense	-	4.97 Cr	5.88 Cr	11.39 Cr	13.20 Cr
Pretax Income	-	35.35 Cr	23.64 Cr	18.01 Cr	8.21 Cr
Tax Provision	-	10.92 Cr	6.40 Cr	5.84 Cr	2.37 Cr
Net Income	-	24.43 Cr	17.25 Cr	12.17 Cr	5.84 Cr
Diluted EPS	2.99	5.01	3.54	2.50	-

Compounded Sales Growth

5 Years:	-1.24%
1 Year:	-3.30%

Compounded Profit Growth

5 Years:	-37.95%
1 Year:	20.80%

Stock Price Performance

1 Year:	+14.76%
6 Months:	+39.49%
3 Months:	+44.52%
1 Month:	+18.86%

Balance Sheet (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Total Assets	-	341.58 Cr	446.82 Cr	472.02 Cr	539.39 Cr
Current Assets	-	190.95 Cr	227.65 Cr	231.31 Cr	275.81 Cr
Cash & Equivalents	-	6.42 Cr	9.60 Cr	1.95 Cr	25.12 Cr
Inventory	-	53.71 Cr	81.26 Cr	86.47 Cr	93.77 Cr
Receivables	-	95.25 Cr	100.17 Cr	106.92 Cr	109.04 Cr
Total Liabilities	-	141.23 Cr	208.08 Cr	219.79 Cr	243.23 Cr
Current Liabilities	-	110.79 Cr	159.43 Cr	166.36 Cr	190.39 Cr
Long Term Debt	-	24.62 Cr	35.60 Cr	40.30 Cr	41.59 Cr
Total Debt	-	62.00 Cr	111.63 Cr	117.68 Cr	125.73 Cr
Total Equity	-	200.35 Cr	238.75 Cr	252.24 Cr	296.15 Cr
Shares Outstanding	-	4.87 Cr	4.87 Cr	4.87 Cr	5.35 Cr

Cash Flows (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Operating Cash Flow	-	38.17 Cr	16.28 Cr	41.15 Cr	49.53 Cr
Investing Cash Flow	-	-36.20 Cr	-73.01 Cr	-39.93 Cr	-56.35 Cr
Financing Cash Flow	-	54.56 L	59.53 Cr	-9.10 Cr	28.19 Cr
Capital Expenditure	-	-36.67 Cr	-73.92 Cr	-40.80 Cr	-44.39 Cr
Free Cash Flow	-	1.50 Cr	-57.65 Cr	35.69 L	5.15 Cr
Net Change in Cash	-	2.51 Cr	2.80 Cr	-7.88 Cr	21.37 Cr

Ratios (Annual)

Figures in %.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Gross Margin %	-	48.6%	51.5%	55.7%	55.8%
Operating Margin %	-	9.1%	7.5%	6.2%	2.7%
Net Margin %	-	6.3%	4.9%	3.2%	1.6%
ROE %	-	12.2%	7.2%	4.8%	2.0%
ROCE %	-	15.3%	9.3%	7.7%	2.9%

Shareholding Pattern

Insiders

71.35%

Institutions

0.00%

Public Float

0.00%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for ZIMLAB

No recent headlines available.

ZIMLAB · Healthcare